Name: QNCX Balance Sheet - Quince Therapeutics Assets & Debt | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Total Assets, Current Assets, Cash and Equivalents, Total Liabilities, Long-term Debt, Short-term Debt, Shareholders Equity, Working Capital, Book Value Per Share

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

QNCX - Quince Therapeutics, Inc.

USD | NASDAQ | Healthcare

QNCX Balance Sheet - Quince Therapeutics Assets & Debt | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Cash And Short Term Investments
Cash And Equivalents	5.8	6.2	-	-	-	-	51.2	24.9	-
Restricted Cash	-	-	-	-	-	-	-	-	-
Short Term Investments	-	-	-	-	-	-	-	-	-
Cash And Short Term Investments	5.8	6.2	-	-	-	-	51.2	24.9	-
Receivables
Accounts Receivable	-	-	-	-	-	-	-	-	-
Current Assets
Inventory	-	-	-	-	-	-	-	-	-
Prepaid Expenses	5.1	3.3	2.4	3.6	4.9
Non-Current Assets
Property, Plant & Equipment Gross	-	-	-	-	-	-	-	-	-
Accumulated Depreciation	0.8	0.6	0.5	0.2
Current Liabilities
Accounts Payable	2.2	2.9	2.0	0.6	4.9	-	3.1	0.5	-
Short Term Debt	18.0	0.0	-	-	-
Non-Current Liabilities
Long Term Debt	0.0	14.3	13.4	0.0	-	-	-	-	-
Operating Lease Liabilities Non-Current	0.3	0.4	0.3	0.0
Common Equity
Common Stock	0.1	0.0	0.0	0.0	0.0	-	0.0	0.0	-
Additional Paid In Capital	418.9	406.6	-	-	-
Supplementary Data
Total Debt	18.0	14.3	13.4	0.0	-	-	-	-	-
Net debt	12.2	8.1	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17
Cash And Short Term Investments
Cash And Equivalents	18.2	5.8	6.5	16.8	7.8	6.2	-	-	-	-	20.8	20.6	42.3	-	21.6

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Current Assets
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Expenses	7.4	5.1	2.9	2.6	2.2	3.3	3.9	4.0	2.6	2.4	1.4	1.0	2.3	-	3.9	4.7	4.8	-
Other Current Assets	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.2	-	0.3	0.4	0.5
Assets Held For Sale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Assets	25.6	22.9	29.2	37.3	33.8	44.0	51.7	63.4	70.4	77.4	85.2	88.5	92.5	-	98.3	99.4

Common Equity
Common Stock	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0	-	0.0	0.0	0.0	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-	-	-
Additional Paid In Capital	435.6	419.0	415.7	413.1	408.1	406.6	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	(424.5)	(460.5)	(421.0)	(407.6)	(391.5)	(376.5)	(364.0)	(358.5)	(330.8)	(319.6)	(310.8)	(305.4)	(300.5)	-	(282.7)	(274.8)	(258.2)
Accumulated Other Comprehensive Income	4.6	5.8	6.3	6.2	2.0	(0.0)	3.4	1.1	1.8	3.0	0.5	0.3	0.0	-	(0.3)	(0.5)
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders Equity	15.7	(35.7)	1.1	11.7	18.6	30.1	44.9	47.0	74.2	85.1	83.1	86.9	90.2	-	104.5	111.5	106.4
Total Equity	15.7	(35.7)	1.1	11.7	18.6	30.1	44.9	47.0	74.2	85.1	83.1	86.9	90.2	-	104.5	111.5	106.4	-

Supplementary Data
Total Debt	0.0	18.0	17.5	17.0	15.3	14.3	14.9	13.8	13.5	13.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net debt	(18.2)	0.3	11.1	0.2	7.5	8.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Working Capital	16.8	(20.3)	3.2	29.9	25.5	36.8	46.3	53.1	60.6	67.9	82.9	86.6	89.4	-	93.3	93.4	86.6	-
Book Value	15.7	(35.7)	1.1	11.7	18.6	30.1	44.9	47.0	74.2	85.1	83.1	86.9	90.2	-	104.5	111.5	106.4	-
Tangible Book Value	15.7	(103.5)	(66.7)	(55.8)	(43.8)	(29.9)	(19.6)	(14.8)	(5.3)	3.8	83.1	86.9	90.2	-	98.6	104.8	-